Awareness about cervical cancer among women residing in urban slums of mysuru city of karnataka, india: a cross-sectional study

Publication date: Available online 17 February 2020Source: Clinical Epidemiology and Global HealthAuthor(s): Hombaiah Chandana, B. Madhu, M.R. Narayana MurthyAbstractIntroductionGlobally, cervical cancer is the 4th most common cancer and is one of the leading cancers causing death in India. Cervical cancer is one of those cancers which can be easily prevented by screening women who are aged above 30 years and by vaccinating young girls against HPV. Lack of awareness about cervical cancer makes early detection and timely screening difficult. Awareness about cervical cancer among people will help us to decide on an appropriate model of behavior change communication to control the disease.Objectives1.To assess the awareness about cervical cancer among women residing in urban slums.2.To find the association between awareness and socio-demographic profiles of women.3.To assess the awareness about HPV vaccination and screening.The cross-sectional study was carried out from October to November of 2018 in the urban slums of Mysuru city. Arbitrarily 5 registered slum areas were selected. 211 consenting participants were enrolled in the study. The Cervical Cancer Awareness Measure (CAM) was used as the survey tool for interviewing women.ResultsAmong 211 women, 26.1% were aware of cervical cancer. Among those who were aware, 9.1% had good knowledge, 27.30 % had average knowledge about cervical cancer and 63.60% had poor knowledge about cervical cancer. Chi-square test showed an associat...
Source: Clinical Epidemiology and Global Health - Category: Epidemiology Source Type: research

Related Links:

rrera-Saldaña María L. Garza-Rodríguez Persistent high-risk human papillomavirus (HR-HPV) infections play a major role in the development of invasive cervical cancer (CC), and screening for such infections is in many countries the primary method of detecting and preventing CC. HPV typing can be used for triage and risk stratification of women with atypical squamous cells of undetermined significance (ASC-US)/low-grade cervical lesions (LSIL), though the current clinical practice in Mexico is to diagnose CC or its preceding conditions mainly via histology and HR-HPV detection. Additional informati...
Source: Viruses - Category: Virology Authors: Tags: Article Source Type: research
Authors: Insamran W, Sangrajrang S Abstract Since 2000 cancer has been the leading cause of death in Thailand. In response to this challenge, the National Cancer Institute of Thailand (NCI), in collaboration with other bodies, has developed and promoted the National Cancer Control Program (NCCP) to provide appropriate policies and practice for the prevention, early detection and treatment of cancer, with optimal supportive care. With plans strongly supported by the Ministry of Public Health, the NCCP envisages integration into the health care system in 6 strategic areas: (1) cancer informatics; (2) primary preventi...
Source: Asian Pacific Journal of Cancer Prevention - Category: Cancer & Oncology Tags: Asian Pac J Cancer Prev Source Type: research
(American Association for the Advancement of Science) Combining a therapeutic vaccine for human papilloma virus (HPV) with two standard chemotherapy drugs may extend survival in patients with advanced, recurrent cervical cancer, according to a phase 1/2 trial involving 77 patients.
Source: EurekAlert! - Cancer - Category: Cancer & Oncology Source Type: news
Therapeutic cancer vaccines have effectively induced durable regressions of premalignant oncogenic human papilloma virus type 16 (HPV16)–induced anogenital lesions. However, the treatment of HPV16-induced cancers requires appropriate countermeasures to overcome cancer-induced immune suppression. We previously showed that standard-of-care carboplatin/paclitaxel chemotherapy can reduce abnormally high numbers of immunosuppressive myeloid cells in patients, allowing the development of much stronger therapeutic HPV16 vaccine (ISA101)–induced tumor immunity. We now show the clinical effects of ISA101 vaccination dur...
Source: Science Translational Medicine - Category: Biomedical Science Authors: Tags: Research Articles Source Type: research
AbstractWe assessed the association of state legislation with  adolescent human papillomavirus (HPV) vaccination rates in states that legislated information dissemination or administration of HPV vaccination. Using insurance claims, we calculated monthly HPV vaccination rates (November 2009–December 2017) among adolescents in states that passed HPV vaccinat ion legislation during that period: Missouri (July 2010), Kentucky (February 2012), Indiana (March 2013), Oregon (June 2013). We used segmented regression to estimate levels and trends of HPV vaccination rates, comparing pre-legislation to post-legislation se...
Source: Journal of Community Health - Category: International Medicine & Public Health Source Type: research
(Karolinska Institutet) The human papillomavirus (HPV) causes, amongst other diseases, cancer of the cervix and oropharynx. A Swedish-Finnish study published in The Journal of Infectious Diseases now shows that the most oncogenic HPV types can be eliminated, but only if both girls and boys are vaccinated. Both genders will be offered vaccination in Sweden as of 2020.
Source: EurekAlert! - Cancer - Category: Cancer & Oncology Source Type: news
This study assessed the safety and tolerability of therapeutic immunization against the HPV viral oncoproteins E6 and E7 in cervical cancer patients following chemoradiation.
Source: International Journal of Radiation Oncology * Biology * Physics - Category: Radiology Authors: Source Type: research
CONCLUSION: The total fraction of malignant and pre-malignant lesions attributed to Human papillomavirus genotypes contained in the nonavalent vaccine is significant in both women and men, which turns this vaccine into a great asset in terms of Public Health. PMID: 32130098 [PubMed - as supplied by publisher]
Source: Acta Medica Portuguesa - Category: General Medicine Tags: Acta Med Port Source Type: research
The first HPV vaccines licensed targeted two HPV types responsible for most cervical cancers. A 9-valent vaccine (9vHPV), targeting 5 additional types, was introduced in 2016 and is currently the only HPV vacc...
Source: Infectious Agents and Cancer - Category: Cancer & Oncology Authors: Tags: Research Article Source Type: research
CONCLUSION: Adults women expressed moderate intention to receive the HPV vaccine. Intervention to address barriers to uptake of the HPV vaccine among adult women in China is warranted. PMID: 32127227 [PubMed - as supplied by publisher]
Source: Vaccine - Category: Allergy & Immunology Authors: Tags: Vaccine Source Type: research
More News: Cancer | Cancer & Oncology | Cancer Vaccines | Cervical Cancer | Education | Epidemiology | Girls | India Health | Statistics | Study | Universities & Medical Training | Vaccines | Women